Suppr超能文献

对活化部分凝血活酶时间(aPTT)基础值延长的患者使用改良功能测定法检测活化蛋白C抵抗。

Use of modified functional assays for activated protein C resistance in patients with basally prolonged aPTT.

作者信息

Montaruli B, Schinco P, Pannocchia A, Giorgianni A, Borchiellini A, Tamponi G, Pileri A

机构信息

Department of Medicine and Experimental Oncology, University of Turin, S. Giovanni Battista Hospital, Italy.

出版信息

Thromb Haemost. 1997 Sep;78(3):1042-8.

PMID:9308751
Abstract

Inherited resistance to activated protein C (APCr) is currently recognized as the most prevalent cause underlying venous thrombophilia, with an estimated prevalence around 20% in thrombotic patients and around 1.8-7% in the general population. A correct laboratory diagnosis of APCr is therefore essential. Two different diagnostic approaches are at present at our disposal: the semi-quantitative plasma test based on the measurement of two aPTTs (in the presence and absence of activated protein C), and the detection of the factor V Arg506 Gln mutation by DNA analysis. In this study we firstly evaluated sensitivity, specificity and diagnostic efficiency of an aPTT-based plasma clotting test (Chromogenix, Sweden) versus DNA analysis; then, since the APC resistance test is invalidated by a basally prolonged aPTT (i.e. during warfarin and heparin therapy or in patients with clotting factor deficiencies or in the presence of a lupus anticoagulant), patient plasmas were conveniently diluted in factor V deficient plasma in order to correct clotting factor abnormalities. Nevertheless, patients with a LA and an aPTT ratio range 1.8-3.17 were still all misclassified. We obtained correct diagnoses in LA positive patients by preincubating plasmas with a mixture of phospholipids; therefore we decided to perform a double modified clotting test adding a mixture of platelet derived phospholipids to samples previously diluted in factor V deficient plasma. The performance characteristics of this novel method with a different aPTT reagent (Behring, Germany) were also evaluated. With this double modified test all patients were correctly classified as negative or positive for factor V mutation in agreement with DNA analysis, irrespectfully of the basal aPTT value and the aPTT reagent employed. We propose this modified version of the APCr clotting test as an easily reproducible, reliable, very sensitive and specific screening test which possibly reduces the need for DNA analysis.

摘要

遗传性活化蛋白C抵抗(APCr)目前被认为是静脉血栓形成倾向的最常见原因,估计在血栓形成患者中的患病率约为20%,在普通人群中约为1.8 - 7%。因此,对APCr进行正确的实验室诊断至关重要。目前我们有两种不同的诊断方法:基于测量两种活化部分凝血活酶时间(aPTT)(存在和不存在活化蛋白C时)的半定量血浆检测,以及通过DNA分析检测因子V Arg506 Gln突变。在本研究中,我们首先评估了基于aPTT的血浆凝血检测(瑞典Chromogenix公司)相对于DNA分析的敏感性、特异性和诊断效率;然后,由于基础aPTT延长会使AP抵抗检测无效(即在华法林和肝素治疗期间,或在凝血因子缺乏的患者中,或存在狼疮抗凝物时),将患者血浆方便地稀释于因子V缺乏的血浆中,以纠正凝血因子异常。然而,狼疮抗凝物阳性且aPTT比值范围在1.8 - 3.17的患者仍全部被错误分类。我们通过将血浆与磷脂混合物预孵育,在狼疮抗凝物阳性患者中获得了正确诊断;因此,我们决定进行双重改良凝血检测,即在先前稀释于因子V缺乏血浆的样本中加入血小板衍生磷脂混合物。还评估了这种使用不同aPTT试剂(德国贝林公司)的新方法的性能特征。通过这种双重改良检测,所有患者根据DNA分析被正确分类为因子V突变阴性或阳性,无论基础aPTT值和所使用的aPTT试剂如何。我们提出这种改良版的APCr凝血检测作为一种易于重复、可靠、非常敏感且特异的筛查检测方法,可能会减少对DNA分析的需求。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验